Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719 plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma
NL-OMON40123Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alpelisib and cetuximab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities, Progression-free survival and 1 more. Started Mar 2013; status: active, not recruiting.
02
Drugs
alpelisibcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON40123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40123.